ANTI-MELANOMA ACTIVITY OF PERPHENAZINE AND PROCHLORPERAZINE IN HUMAN COLO829 AND C32 CELL LINES
Description
Cutaneous melanoma is fairly common (only about 1% of skin cancers), but is the deadliest malignant tumor. Moreover, amelanotic type of melanoma is very difficult for clinical diagnosis. The standard therapy can cause a lot of side effects e.g. nausea, vomiting and headaches, which means that novel and effective strategies are required. Interestingly, phenothiazine derivatives possess sedative, antiemetic, and anticancer activity. In the present study, we explore the anticancer effect of perphenazine and prochlorperazine in human melanotic (COLO829) and amelanotic (C32) melanoma cells suggesting that prochlorperazine inhibits cell viability in a concentration-dependent manner, impairs migration, and decreases tyrosinase and MITF amount. Moreover, the analyzed drugs decrease/increase MITF amount depending on type of melanoma. We demonstrated that the decrease of MITF and tyrosinase protein induces migration inhibition of C32 cells, and suggests the ability of those drugs to restore cancer cell sensitivity to treatment. The ability of prochlorperazine to containing the spread of the amelanotic melanoma in vivo may be helpful in the development of a new and effective antimelanoma therapy.